MANHASSET, N.Y. - The U.S. issued 4,996 nanotechnology patents in 2005, but a report found that the rate of nanotech patents increased only 4 percent last year after previously exceeding 20 percent.

Still, the number of patent applications for nanotechnology continued to increase in 2005 , growing by 52 percent to 2,714 applications.

Bottlenecks at the U.S. Patent & Trademark Office center on crowded patent domains with overlapping claims. Pendency rates-the time from the submission of a nanotech patent application to issuance-grew to nearly four years on average, up from two and half years in 1993.

The report by Lux Research and Foley & Lardner LLP, entitled "Nanotech IP Battles Worth Fighting," warns that "when the dust settles from this influx of inventions, many patent holders will be wondering just how valuable their innovations are in densely crowded and overlapping areas."

The report reviewed 2,738 patents covering 52,148 relevant claims crossing seven application categories. It identified applications worth fighting over and those with relatively low payoff.

Among the report's highlights are that carbon nanotube and quantum dot applications in electronics, where many crowded and vulnerable patents indicate a high likelihood of legal wrangling, are worth defending. Large potential markets for nanomaterials justify the cost of navigating the unfavorable patent outlook, the report found.

Dendrimers along with ceramic and metal nanoparticles are also promising for their potential applications.

According to the report, opportunities also exist in energy applications for ceramic nanoparticles like high-performance cathodes in the $48 billion battery market. Nanowires are also expected to have electronics applications.

The report also warns that "patent trolls" are starting to invade the nanotechnology market. Patent trolls are companies that buy patents for the sole purpose of enforcing them, rather than developing the technology into products.

http://www.eetimes.com/news/latest/showArticle.jhtml?articleID=191100461

St. Louis, July 27, 2006 -- In laboratory tests, one very low dose of a drug was enough to show an effect on notoriously tenacious artery-clogging plaques. What kind of drug is that potent?

It's not so much the drug itself as how it was delivered. Fumagillin -- a drug that can inhibit the growth of new blood vessels that feed atherosclerotic plaques -- was sent directly to the base of plaques by microscopically small spheres called nanoparticles developed by researchers at Washington University School of Medicine in St. Louis.

"Previously we reported that we can visualize plaques using our nanoparticle technology, but this is the first time we've demonstrated that the nanoparticles can also deliver a drug to a disease site in a living organism," says Patrick Winter, Ph.D., research assistant professor of medicine. "After a single dose in laboratory rabbits, fumagillin nanoparticles markedly reduced the growth of new blood vessels that feed plaques."

The researchers report their findings in the September issue of the journal Arteriosclerosis, Thrombosis, and Vascular Biology, and the article is now available on line.

An atherosclerosis plaque results when a buildup of cholesterol, inflammatory cells and fibrous tissue forms inside an artery. If a plaque ruptures, it can block blood flow to the heart or brain, causing heart attack or stroke.

While growing, plaques require an influx of nutrients, fats and cells, so they develop their own blood supply -- minute blood vessels that grow within the wall of arteries and penetrate the plaque. Many believe that cutting off this blood supply could stabilize or reduce plaques. In previous studies, fumagillin has been shown to be an effective agent for stopping the process that creates new blood vessels.

Riding on the nanoparticles, fumagillin is carried to the site of new blood vessel formation and stays there thanks to a fellow nanoparticle passenger -- a component that fastens the nanoparticles to cells found in newly developing blood vessels. Stuck in this position, the nanoparticle drops its load of fumagillin, concentrating it at the site of the atherosclerotic plaque.

In this study, the single dosage of fumagillin each rabbit received was 50,000 times lower than the total fumagillin dose used in an earlier experiment by another research group and yet reduced the growth of new blood vessels in plaques by 60 to 80 percent.

"Fumagillin can have neurocognitive side effects, causing injury to the brain at high doses," Winter says. "The ability of the nanoparticles to concentrate the drug at the disease site allows the dose to be lowered. This could open the door for a lot of drugs that have failed to be approved because they caused too many side effects at a higher dose. It might pay to look at these drugs again and ask if placing them on these nanoparticles can help them be effective at a lower dose and clinically useful."

The nanoparticles are the invention of Samuel Wickline, M.D., professor of medicine, of biomedical engineering, of physics and of cell biology and physiology, and Gregory Lanza, M.D., Ph.D., associate professor of medicine and biomedical engineering. Both are heart specialists at Barnes-Jewish Hospital.

The microscopic spheres are capable of carrying a variety of components at the same time and can be detected with standard MRI scans, making them useful for imaging disease sites while simultaneously treating them. Using the nanoparticles, a physician can confirm a drug has reached the desired location, measure the amount of drug at the site, and later check to see if the drug has affected the disease.

In the current study, the researchers fed rabbits a high-cholesterol diet for 80 days before treatment with fumagillin nanoparticles. The diet caused numerous small plaques in the rabbits' aortas, but the plaques were considered to be at an early stage of growth. By demonstrating the utility of the nanoparticles for early intervention of atherosclerosis, the research group hopes that they can help alleviate the need for more invasive treatment of later-stage atherosclerosis.

"We wanted to go after the early stages of the disease when patients don't yet need immediate intervention to prevent serious cardiac problems," Winter says. "We think fumagillin nanoparticles potentially could be incorporated into a protocol that includes lipid-lowering statin drugs or dietary changes." Next, the research group plans to study the effect of fumagillin nanoparticles in the treatment of cancerous tumors. According to Winter, the use of inhibitors of blood vessel growth is a well-accepted therapy for cancer, suggesting the nanotechnology may prove beneficial in cancer therapy.

http://www.eurekalert.org/pub_releases/2006-07/wuso-nel072706.php